The primary aim of this non interventional study is to assess the independent prognostic role on overall survival of primary tumour 18F-FDG uptake value (SUVmax) measured on 18fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in patients with non-metastatic non-small cell lung cancers treated with curative intent, taking into account the other conventional prognostic factors (performance status, age, sex, disease stage).

Inclusion Criteria:

• Pathologically demonstrated NSCLC
• Stage I-III treated by curative treatment by surgery with or without chemotherapy (induction or adjuvant) or by chemoradiotherapy
• Inoperable patients treated by exclusive radiotherapy
• A whole-body (skull base to mid thighs) FDG-PET or a combined FDG-PET/CT on a dedicated machine, performed before any anticancer treatment
• FDG-PET or combined FDG-PET/CT has to be previously standardised according to the procedure described in appendix IV
• Written informed consent
• Accessibility to follow-up
• Age > 18 years

Exclusion Criteria:

• Prior anticancer treatment (surgery, radiotherapy or chemotherapy)
• Stage IV NSCLC
• A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5-year disease free interval)
• Uncontrolled diabetes mellitus (fast glycaemia above 130 mg/dl)
• Pregnancy and lactating woman
• Unavailability to send a copy of the PET or PET-CT (DICOM format) to the data centre

All patients presenting with non metastatic non small cell lung carcinoma, treated in the participating centres with curative intent